EA201000784A1 - Антагонисты пути hedgehog и их терапевтические применения - Google Patents

Антагонисты пути hedgehog и их терапевтические применения

Info

Publication number
EA201000784A1
EA201000784A1 EA201000784A EA201000784A EA201000784A1 EA 201000784 A1 EA201000784 A1 EA 201000784A1 EA 201000784 A EA201000784 A EA 201000784A EA 201000784 A EA201000784 A EA 201000784A EA 201000784 A1 EA201000784 A1 EA 201000784A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic applications
hedgehog antagonists
hedgehog
antagonists
pharmaceutical composition
Prior art date
Application number
EA201000784A
Other languages
English (en)
Other versions
EA017918B1 (ru
Inventor
Рассел Джон Томас
Гал.ла Перикот Мор
Джакомо Минетто
Анетта Корнелия Баккер
Пьетро Ферруцци
Original Assignee
СИЕНА БИОТЕК С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИЕНА БИОТЕК С.п.А. filed Critical СИЕНА БИОТЕК С.п.А.
Publication of EA201000784A1 publication Critical patent/EA201000784A1/ru
Publication of EA017918B1 publication Critical patent/EA017918B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Гетероциклические соединения, модулирующие сигнальный путь hedgehog, их фармацевтическая композиция и их терапевтические применения.
EA201000784A 2007-12-13 2008-12-10 Антагонисты пути hedgehog и их терапевтические применения EA017918B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07024218 2007-12-13
PCT/EP2008/010470 WO2009074300A2 (en) 2007-12-13 2008-12-10 Hedgehog pathway antagonists and therapeutic applications thereof

Publications (2)

Publication Number Publication Date
EA201000784A1 true EA201000784A1 (ru) 2010-12-30
EA017918B1 EA017918B1 (ru) 2013-04-30

Family

ID=39432963

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000784A EA017918B1 (ru) 2007-12-13 2008-12-10 Антагонисты пути hedgehog и их терапевтические применения

Country Status (16)

Country Link
US (1) US8592463B2 (ru)
EP (1) EP2227456A2 (ru)
JP (1) JP5620821B2 (ru)
CN (1) CN101896472A (ru)
AR (1) AR069652A1 (ru)
AU (1) AU2008335880B2 (ru)
BR (1) BRPI0820856A2 (ru)
CA (1) CA2709203A1 (ru)
CO (1) CO6210735A2 (ru)
CR (1) CR11481A (ru)
EA (1) EA017918B1 (ru)
IL (1) IL206298A0 (ru)
NZ (1) NZ586121A (ru)
TW (1) TW200930370A (ru)
WO (1) WO2009074300A2 (ru)
ZA (1) ZA201004185B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
AU2008345097A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
AR070047A1 (es) * 2007-12-27 2010-03-10 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010126811A1 (en) * 2009-04-27 2010-11-04 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
ES2567134T3 (es) 2009-08-05 2016-04-20 Infinity Pharmaceuticals, Inc. Transaminación enzimática de análogos de ciclopamina
WO2011084985A1 (en) 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
EP2468726B1 (en) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FI20115785A0 (fi) * 2011-08-08 2011-08-08 Thermo Fisher Scientific Oy Menetelmä ja laite automaattiseen analyysiin
WO2013021101A1 (en) 2011-08-08 2013-02-14 Thermo Fisher Scientific Oy Method and apparatus for automated analysis
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013052395A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT2914296T (pt) 2012-11-01 2018-10-30 Infinity Pharmaceuticals Inc Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
MX2015016277A (es) 2013-05-30 2016-08-11 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
US9663499B2 (en) 2013-06-07 2017-05-30 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
BR112016007467B1 (pt) 2013-10-04 2022-09-20 Infinity Pharmaceuticals, Inc Compostos heterocíclicos e usos dos mesmos
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3250036B1 (en) 2014-12-10 2021-05-12 The Scripps Research Institute Small molecule inhibitors of fibrosis
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CN110494431B (zh) * 2017-09-30 2022-11-04 苏州浦合医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CN110016054B (zh) * 2019-03-15 2021-10-22 四川大学 含磷氮苯并杂环结构的离子单体、用其阻燃的共聚酯型离聚物及它们的制备方法和应用
CN114790177B (zh) * 2021-01-26 2024-03-26 首都医科大学附属北京天坛医院 新型Hedgehog信号通路抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28787A (id) * 1998-11-03 2001-07-05 Basf Ag 2-fenilbenzimidazol tersubstitusi, pembuatannya dan penggunaannya
DE60221866T2 (de) * 2001-10-19 2008-05-29 Ortho-Mcneil Pharmaceutical, Inc. 2-PHENYL BENZIMIDAZOLE UND IMIDAZO-i4,5ö-PYRIDINE ALS CDS1/CHK2-INHIBITOREN UND ADJUVANTIEN IN DER CHEMOTHERAPIE ODER STRAHLUNGSTHERAPIE ZUR BEHANDLUNG VON KREBS
ES2373875T3 (es) * 2002-03-05 2012-02-09 Transtech Pharma, Inc. Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage.
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用

Also Published As

Publication number Publication date
TW200930370A (en) 2009-07-16
NZ586121A (en) 2012-03-30
CA2709203A1 (en) 2009-06-18
JP2011506366A (ja) 2011-03-03
AU2008335880A1 (en) 2009-06-18
EP2227456A2 (en) 2010-09-15
WO2009074300A3 (en) 2009-10-01
US20100286114A1 (en) 2010-11-11
IL206298A0 (en) 2010-12-30
US8592463B2 (en) 2013-11-26
CR11481A (es) 2010-10-15
ZA201004185B (en) 2011-10-26
AU2008335880B2 (en) 2014-03-13
WO2009074300A8 (en) 2009-11-19
CO6210735A2 (es) 2010-10-20
BRPI0820856A2 (pt) 2019-05-14
EA017918B1 (ru) 2013-04-30
JP5620821B2 (ja) 2014-11-05
AR069652A1 (es) 2010-02-10
CN101896472A (zh) 2010-11-24
WO2009074300A2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
EA201000784A1 (ru) Антагонисты пути hedgehog и их терапевтические применения
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
EA200802008A1 (ru) Фармацевтические композиции
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170227A1 (ru) Имидазолкарбоксамиды
BRPI0810646A2 (pt) " compostos farmacêuticos ".
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA201000258A1 (ru) Новые гербициды
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
NO20091299L (no) Substituerte sulfonamidderivater
CR11057A (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
DK2254873T3 (da) Benzodiazepinforbindelse og farmaceutisk sammensætning.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU